Titan Common Stock Total Equity vs Net Receivables Analysis

TTNP Stock

USD 6.64 0.42 5.95%

Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Common Stock Total Equity and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Common Stock Total Equity vs Net Receivables

Common Stock Total Equity vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Common Stock Total Equity account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Titan Pharmaceuticals' Common Stock Total Equity and Net Receivables is 0.72. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Common Stock Total Equity and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Titan Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Common Stock Total Equity i.e., Titan Pharmaceuticals' Common Stock Total Equity and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Net Receivables

Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 06/06/2024, Enterprise Value Over EBITDA is likely to grow to 0.0006, while Issuance Of Capital Stock is likely to drop slightly above 7.2 M.

Titan Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Common Stock Total Equity	Short Term Investments	Property Plant Equipment
Total Assets		0.59	-0.32	0.71	-0.11	0.69	-0.64	-0.02	0.74	0.95	0.08	-0.35	0.97	0.85	-0.47	0.45	-0.56	0.59	0.99	0.33	-0.33	0.09	0.7	0.66	-0.33	0.68
Short Long Term Debt Total	0.59		-0.35	0.68	-0.65	0.43	0.17	0.47	0.73	0.43	0.33	-0.17	0.46	0.66	-0.75	0.79	-0.86	0.82	0.54	0.69	0.17	-0.33	0.73	0.78	0.13	0.12
Other Current Liab	-0.32	-0.35		-0.2	0.2	0.09	0.13	0.12	-0.44	-0.36	0.3	0.15	-0.34	-0.5	-0.12	-0.36	0.32	-0.33	-0.36	-0.24	0.31	0.18	-0.48	-0.45	0.29	-0.15
Total Current Liabilities	0.71	0.68	-0.2		-0.62	0.65	-0.11	0.3	0.54	0.62	0.42	-0.21	0.64	0.58	-0.49	0.66	-0.58	0.85	0.65	0.44	0.11	0.16	0.48	0.52	0.09	0.55
Total Stockholder Equity	-0.11	-0.65	0.2	-0.62		-0.03	-0.61	-0.28	-0.25	-0.01	-0.17	0.31	-0.03	-0.18	0.3	-0.9	0.32	-0.87	-0.09	-0.22	-0.23	0.16	-0.15	-0.19	-0.19	0.15
Property Plant And Equipment Net	0.69	0.43	0.09	0.65	-0.03		-0.4	0.23	0.59	0.52	0.53	-0.1	0.56	0.54	-0.7	0.15	-0.49	0.36	0.61	0.34	0.01	0.36	0.45	0.46	0.0	0.8
Net Debt	-0.64	0.17	0.13	-0.11	-0.61	-0.4		0.39	-0.32	-0.73	0.2	0.16	-0.72	-0.48	-0.11	0.31	0.06	0.17	-0.67	0.04	0.54	-0.35	-0.36	-0.28	0.49	-0.66
Retained Earnings	-0.02	0.47	0.12	0.3	-0.28	0.23	0.39		0.12	-0.19	0.9	0.67	-0.17	0.02	-0.53	0.11	-0.58	0.2	-0.15	0.81	0.92	-0.24	0.1	0.27	0.92	-0.11
Accounts Payable	0.74	0.73	-0.44	0.54	-0.25	0.59	-0.32	0.12		0.58	0.11	-0.38	0.61	0.93	-0.58	0.52	-0.73	0.57	0.73	0.47	-0.24	-0.02	0.8	0.79	-0.24	0.44
Cash	0.95	0.43	-0.36	0.62	-0.01	0.52	-0.73	-0.19	0.58		-0.1	-0.36	0.99	0.75	-0.24	0.36	-0.42	0.49	0.97	0.21	-0.45	0.1	0.64	0.58	-0.44	0.64
Non Current Assets Total	0.08	0.33	0.3	0.42	-0.17	0.53	0.2	0.9	0.11	-0.1		0.6	-0.07	0.02	-0.57	-0.01	-0.46	0.16	-0.06	0.66	0.85	0.08	0.01	0.17	0.85	0.21
Non Currrent Assets Other	-0.35	-0.17	0.15	-0.21	0.31	-0.1	0.16	0.67	-0.38	-0.36	0.6		-0.36	-0.41	0.02	-0.51	-0.11	-0.44	-0.43	0.44	0.75	-0.04	-0.24	-0.1	0.77	-0.24
Cash And Short Term Investments	0.97	0.46	-0.34	0.64	-0.03	0.56	-0.72	-0.17	0.61	0.99	-0.07	-0.36		0.75	-0.29	0.37	-0.45	0.51	0.98	0.23	-0.44	0.11	0.66	0.6	-0.43	0.64
Net Receivables	0.85	0.66	-0.5	0.58	-0.18	0.54	-0.48	0.02	0.93	0.75	0.02	-0.41	0.75		-0.43	0.49	-0.63	0.57	0.85	0.41	-0.32	-0.05	0.76	0.72	-0.31	0.55
Common Stock Shares Outstanding	-0.47	-0.75	-0.12	-0.49	0.3	-0.7	-0.11	-0.53	-0.58	-0.24	-0.57	0.02	-0.29	-0.43		-0.39	0.73	-0.47	-0.38	-0.6	-0.28	0.26	-0.53	-0.6	-0.24	-0.22
Non Current Liabilities Total	0.45	0.79	-0.36	0.66	-0.9	0.15	0.31	0.11	0.52	0.36	-0.01	-0.51	0.37	0.49	-0.39		-0.44	0.95	0.45	0.22	-0.06	-0.21	0.41	0.4	-0.1	0.0
Other Stockholder Equity	-0.56	-0.86	0.32	-0.58	0.32	-0.49	0.06	-0.58	-0.73	-0.42	-0.46	-0.11	-0.45	-0.63	0.73	-0.44		-0.53	-0.49	-0.91	-0.24	0.23	-0.86	-0.94	-0.24	-0.18
Total Liab	0.59	0.82	-0.33	0.85	-0.87	0.36	0.17	0.2	0.57	0.49	0.16	-0.44	0.51	0.57	-0.47	0.95	-0.53		0.57	0.33	0.0	-0.08	0.48	0.48	-0.03	0.22
Total Current Assets	0.99	0.54	-0.36	0.65	-0.09	0.61	-0.67	-0.15	0.73	0.97	-0.06	-0.43	0.98	0.85	-0.38	0.45	-0.49	0.57		0.24	-0.45	0.07	0.7	0.64	-0.45	0.65
Short Term Debt	0.33	0.69	-0.24	0.44	-0.22	0.34	0.04	0.81	0.47	0.21	0.66	0.44	0.23	0.41	-0.6	0.22	-0.91	0.33	0.24		0.55	-0.3	0.63	0.76	0.57	0.07
Other Current Assets	-0.33	0.17	0.31	0.11	-0.23	0.01	0.54	0.92	-0.24	-0.45	0.85	0.75	-0.44	-0.32	-0.28	-0.06	-0.24	0.0	-0.45	0.55		-0.17	-0.27	-0.1	1.0	-0.26
Property Plant And Equipment Gross	0.09	-0.33	0.18	0.16	0.16	0.36	-0.35	-0.24	-0.02	0.1	0.08	-0.04	0.11	-0.05	0.26	-0.21	0.23	-0.08	0.07	-0.3	-0.17		-0.14	-0.17	-0.15	0.46
Common Stock	0.7	0.73	-0.48	0.48	-0.15	0.45	-0.36	0.1	0.8	0.64	0.01	-0.24	0.66	0.76	-0.53	0.41	-0.86	0.48	0.7	0.63	-0.27	-0.14		0.98	-0.26	0.3
Common Stock Total Equity	0.66	0.78	-0.45	0.52	-0.19	0.46	-0.28	0.27	0.79	0.58	0.17	-0.1	0.6	0.72	-0.6	0.4	-0.94	0.48	0.64	0.76	-0.1	-0.17	0.98		-0.08	0.26
Short Term Investments	-0.33	0.13	0.29	0.09	-0.19	0.0	0.49	0.92	-0.24	-0.44	0.85	0.77	-0.43	-0.31	-0.24	-0.1	-0.24	-0.03	-0.45	0.57	1.0	-0.15	-0.26	-0.08		-0.24
Property Plant Equipment	0.68	0.12	-0.15	0.55	0.15	0.8	-0.66	-0.11	0.44	0.64	0.21	-0.24	0.64	0.55	-0.22	0.0	-0.18	0.22	0.65	0.07	-0.26	0.46	0.3	0.26	-0.24

Click cells to compare fundamentals

Titan Pharmaceuticals Account Relationship Matchups

Titan Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Short Long Term Debt Total	4.4M	809K	299K	187K	565K	536.8K
Other Current Liab	1.9M	2.0M	1.5M	1.6M	519K	493.1K
Total Current Liabilities	3.6M	4.2M	2.7M	2.6M	1.4M	1.4M
Total Stockholder Equity	1.4M	3.5M	5.1M	1.4M	6.6M	6.3M
Property Plant And Equipment Net	1.2M	759K	717K	407K	68K	64.6K
Net Debt	(782K)	(4.6M)	(5.7M)	(2.8M)	(6.2M)	(6.5M)
Retained Earnings	(349.0M)	(367.3M)	(376.1M)	(386.3M)	(391.8M)	(372.2M)
Accounts Payable	1.4M	1.3M	795K	695K	348K	330.6K
Cash	5.2M	5.4M	6.0M	2.9M	6.8M	8.3M
Non Current Assets Total	1.2M	759K	765K	455K	68.0K	64.6K
Non Currrent Assets Other	794K	(1.2M)	(759K)	48K	(1.0)	(0.95)
Cash And Short Term Investments	5.2M	5.4M	6.0M	2.9M	6.8M	6.4M
Net Receivables	993K	884K	112K	36K	1.0M	1.6M
Common Stock Shares Outstanding	1.3K	188.7K	486.5K	671.7K	752K	789.6K
Liabilities And Stockholders Equity	9.5M	8.1M	8.0M	4.1M	8.1M	7.7M
Non Current Liabilities Total	3.8M	4.5M	332K	187K	65K	0.0
Other Stockholder Equity	350.4M	370.8M	381.2M	387.6M	398.5M	418.4M
Total Liab	8.1M	4.6M	2.9M	2.7M	1.4M	1.4M
Total Current Assets	8.3M	7.3M	7.2M	3.6M	8.0M	7.6M
Short Term Debt	272K	477K	112K	122K	565K	1.1M
Other Current Assets	1.1M	522K	480K	314K	199K	189.1K
Property Plant And Equipment Gross	1.2M	618K	2.1M	2M	774K	883.3K
Common Stock	57K	7K	10K	15K	1K	950.0
Property Plant Equipment	794K	1.2M	759K	717K	824.6K	826.4K
Long Term Debt	3.6M	3.8M	4.0M	332K	298.8K	283.9K
Retained Earnings Total Equity	(323.3M)	(332.6M)	(349.0M)	(367.3M)	(330.6M)	(347.1M)
Net Tangible Assets	6.8M	1.4M	3.5M	5.1M	4.6M	4.7M
Capital Surpluse	26.3M	339.4M	350.4M	370.8M	426.4M	447.7M
Net Invested Capital	5.5M	4.2M	5.1M	1.4M	7.1M	4.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Titan Common Stock Total Equity vs Net Receivables Analysis

Common Stock Total Equity vs Net Receivables

Common Stock Total Equity vs Net Receivables Correlation Analysis

Correlation Coefficient

Common Stock Total Equity

Net Receivables

Titan Pharmaceuticals fundamental ratios Correlations

Titan Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Titan Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for Titan Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Investments	+ 1.0	Other Current Assets
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments
Common Stock Total Equity	+ 0.98	Common Stock
Cash And Short Term Investments	+ 0.97	Total Assets

Common Stock Total Equity	- 0.94	Other Stockholder Equity
Short Term Debt	- 0.91	Other Stockholder Equity
Non Current Liabilities Total	- 0.9	Total Stockholder Equity
Total Liab	- 0.87	Total Stockholder Equity
Common Stock	- 0.86	Other Stockholder Equity
Other Stockholder Equity	- 0.86	Short Long Term Debt Total